Serotonergic dysfunction in schizophrenia assessed by the loudness dependence measure of primary auditory cortex evoked activity

Schizophrenia Research

Volumn 64, Issue 2-3, 2003, Pages 115-124

  Juckel, Georg ^a,b   Gallinat, Jürgen ^a   Riedel, Michael ^a   Sokullu, Safet ^a   Schulz, Carl ^a   Möller, Hans Jürgen ^a   Müller, Norbert ^a   Hegerl, Ulrich ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Atypical neuroleptics; Auditory evoked potentials; Loudness dependence; Schizophrenia; Serotonin

Indexed keywords

CHLORAL HYDRATE; CLOZAPINE; HALOPERIDOL; LORAZEPAM; OLANZAPINE; OXAZEPAM; SEROTONIN 2 ANTAGONIST;

ADULT; ARTICLE; AUDITORY CORTEX; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EVOKED AUDITORY RESPONSE; FEMALE; HUMAN; LOUDNESS; MALE; MENTAL PATIENT; NEUROTRANSMISSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGHT HEMISPHERE; SCHIZOPHRENIA; SEROTONINERGIC TRANSMISSION;

EID: 0242627577     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(03)00016-1     Document Type: Article

References (65)

1. Abi-Dargham A., Laruelle M., Aghajanian G.K., Charney D., Krystal J. The role of serotonin in the pathophysiology and treatment of schizophrenia. J. Neuropsychiatry Clin. Neurosci. 9:1997;1-17.
2. Aghajanian G.K., Marek G.J. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res. Rev. 31:2000;302-312.
3. Agren H., Mefford I.N., Rudorfer M.V., Linnoila M., Potter W.Z. Interacting neurotransmitter systems. A non-experimental approach to the 5HIAA-HVA correlation in human CSF. J. Psychiatry Res. 20:1986;175-193.
4. Andersen P.H., Braestrup C. Evidence for different states of the dopamine D1 receptor: clozapine and fluperlapine may preferentially label an adenylate-cyclase-coupled state of the D1 receptor. J. Neurochem. 47:1986;1822-1831.
5. Asarnow R.F., Cromwell R.L., Rennick P.M. Cognitive and evoked response measures of information processing in schizophrenics with and without a family history of schizophrenia. J. Nerv. Ment. Dis. 166:1978;719-730.
6. Azmitia E.C., Gannon P.J. The primate serotonergic system: a review of human and animal studies and a report on macaca fascicularis. Adv. Neurol. 43:1986;407-468.
7. Baribeau J.C., Laurent J.P., Braun I. Individual differences, the augmenting/reducing effect and selective attention in schizophrenia. Res. Commun. Psychol. Psych. Behav. 13:1988;17-33.
8. Bengtsson H.J., Kullberg A., Millan M.J., Hjorth S. The role of 5-HT1A autoreceptors and alpha1-adrenoreceptors in the modulation of 5-HT release: III. Clozapine and the novel putative antipsychotic S 16924. Neuropharmacology. 37:1998;349-356.
9. Bennett M.E. Monaminergic synapses and schizophrenia: 45 years of neuroleptics. J. Psychopharmacol. 12:1998;289-304.
10. Buchsbaum M.S., Silverman J. Stimulus intensity control and the cortical evoked response. Psychosom. Med. 30:1968;12-22.
11. Buchsbaum M.S., Coppola R., Gershon E.S., van Kammen D.P., Nurnberger J.I. Evoked potential measures of attention and psychopathology. Adv. Biol. Psychiatry. 6:1981;186-194.
12. Buchsbaum M.S., Awsare S.V., Holcomb H.H., Delisi L.E., Hazlett E., Carpenter W.T., Pickar D., Morihisa J.M. Topographic differences between normals and schizophrenics: the N120 evoked potential component. Neuropsychobiology. 15:1986;1-6.
13. Bymaster F., Perry K.W., Nelson D.L., Wong D.T., Rasmussen K., Moore N.A., Calligaro D.O. Olanzapine: a basic science update. Br. J. Psychiatry Suppl. 37:1999;36-40.
14. Carlsson A., Waters N., Carlsson M.L. Neurotransmitter interactions in schizophrenia - therapeutic implications. Biol. Psychiatry. 46:1999;1388-1395.
15. Collegium Internationale Psychiatriae Scalarum (CIPS) International Scales for Psychiatry, 3rd ed. 1986;Beltz, Weinheim.
16. Connolly J.F., Gruzelier J.H., Manchanda R., Hirsch S.R. Visual evoked potentials in schizophrenia. Intensity effects and hemispheric asymmetry. Br. J. Psychiatry. 142:1983;152-155.
17. Croft R.J., Klugman A., Baldeweg T., Gruzelier J.H. Electrophysiological evidence of serotonergic impairment in long-term MDMA ("ecstasy") users. Am. J. Psychiatry. 158:2001;1687-1692.
18. Eastwood S.L., Burner P.W., Gittins R., Baker K., Harrison P.J. Expression of serotonin 5-HAT(2A) receptors in the human cerebellum and alterations in schizophrenia. Synapse. 42:2001;104-114.
19. Ferre S., Artigas F. Clozapine decreases serotonin extracellular levels in the nucleus accumbens by a dopamine receptor-independent mechanism. Neurosci. Lett. 187:1995;61-64.
20. Gallinat J., Bottlender R., Juckel G., Munke-Puchner A., Stotz G., Kuss H.J., Mavrogiorgou P., Hegerl U. The loudness dependency of the auditory evoked N1/P2-component as a predictor of the acute SSRI response in depression. Psychopharmacology. 148:2000;404-411.
21. Gallinat J., Senkowski D., Wernicke C., Juckel G., Becker I., Sander T., Smolka M., Hegerl U., Rommelspacher H., Winterer G., Herrmann W.M. Allelic variants of the functional promoter polymorphism of the human serotonin transporter gene is associated with auditory cortical stimulus processing. Neuropsychopharmacology. 28:2003;530-532.
22. Glenthoj B.Y., Hemmingsen R. Transmitter dysfunction during the process of schizophrenia. Acta Psychiatr. Scand., Suppl. 395:1999;105-112.
23. Gründer G., Vernaleken I., Benkert O. Which properties make a neuroleptic "atypical"? Nervenarzt. 72:2001;833-843.
24. Gruzelier J.H., Jutai J.W., Connolly J.F., Hirsch S.R. Cerebral asymmetries and stimulus intensity relationships in EEG spectra of VEPs in unmedicated schizophrenic patients: relationship with active and withdrawn syndromes. Int. J. Psychophysiol. 15:1993;239-246.
25. Harrison P.J. Neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. Br. J. Psychiatry. 174(Suppl. 38):1999;12-22.
26. Hegerl U., Juckel G. Intensity dependence of auditory evoked potentials as indicator of central serotonergic neurotransmission - a new hypothesis. Biol. Psychiatry. 33:1993;173-187.
27. Hegerl U., Gallinat J., Mrowinski D. Intensity dependence of auditory evoked dipole source activity. Int. J. Psychophysiol. 17:1994;1-13.
28. Herrmann M.J., Sonnek G., Weijers H.G., Wiesbeck G.A., Boning J., Fallgatter A.J. Electrophysiological indication for a link between serotonergic neurotransmission and personality in alcoholism. Prog. Neuropsychopharmacol. Biol. Psychiatry. 26:2002;157-161.
29. Hertel P., Nomikos G.G., Svensson T.H. Risperidone inhibits 5-hydroxytryptaminergic neuronal activity in the dorsal raphe nucleus by local release of 5-hydroxytryptamine. Br. J. Pharmacol. 122:1997;1639-1646.
30. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., Meltzer H.Y. 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 76:2001;1521-1531.
31. Joyce J.N., Shane A., Lexow N., Winokur A., Casanova M.F., Kleinman J.E. Serotonin uptake sites and serotonin receptors are altered in the limbic system in schizophrenics. Neuropsychopharmacology. 8:1993;315-336.
32. Juckel G., Molnar M., Hegerl U., Csepe V., Karmos G. Auditory evoked potentials as indicator of brain serotonergic activity-first evidence in behaving cats. Biol. Psychiatry. 41:1997;1181-1195.
33. Juckel G., Hegerl U., Molnár M., Csépe V., Karmos G. Auditory evoked potentials reflect serotonergic neuronal activity - a study in behaving cats administered drugs acting on 5-HT1A autoreceptors in the dorsal raphe nucleus. Neuropsychopharmacology. 21:1999;710-716.
34. Jutai J.W., Gruzelier J.H., Connolly J.F., Manchanda R., Hirsch S.R. Schizophrenia and spectral analysis of the visual evoked potential. Br. J. Psychiatry. 145:1984;496-501.
35. Kapur S., Zipursky R.B., Remington G., Jones C., DaSilva J., Wilson A.A., Houle S. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am. J. Psychiatry. 155:1998;921-928.
36. Kapur S., Zipursky R.B., Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry. 156:1999;286-293.
37. Katsanis J., Iacono W.G., Beiser M. Visual event-related potentials in first-episode psychotic patients and their relatives. Psychophysiology. 33:1996;207-217.
38. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13:1987;261-276.
39. Landau S.G., Buchsbaum M.S., Carpenter W., Strauss J., Sacks M. Schizophrenia and stimulus intensity control. Arch. Gen. Psychiatry. 32:1975;1239-1245.
40. Lewis D.A., Campbell M.J., Foote S.L., Morrison J.H. The monoaminergic innervation of primate neocortex. Hum. Neurobiol. 5:1986;181-188.
41. Meltzer H.Y. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology. 99:1989;S18-S27.
42. Meltzer H.Y. The mechanism of action of novel antipsychotic drugs. Schizophr. Bull. 17:1991;263-287.
43. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 21:1999;106S-115S.
44. Moore P., Landolt H.P., Seifritz E., Clark C., Bhatti T., Kelsoe J., Rapaport M., Gillin J.C. Clinical and physiological consequences of rapid tryptophan depletion. Neuropsychopharmacology. 23:2000;601-622.
45. Mowry B.J., Nancarrow D.J. Molecular genetics of schizophrenia. Clin. Exp. Pharmacol. Physiol. 28:2001;66-69.
46. Murphy D.L. Peripheral indices of central serotonin function in human. Ann. N.Y. Acad. Sci. 600:1990;282-296.
47. Nash J.F., Meltzer H.Y. Neuroendocrine studies in psychiatric disorders: the role of serotonin. Brown S.L., van Praag H.M. The Role of Serotonin in Psychiatric Disorders. 1991;57-90 Brunner/Mazel, New York.
48. Ngan E.T., Yatham L.N., Ruth T.J., Liddle P.F. Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: a PET study using [(18)F]setoperone. Am. J. Psychiatry. 157:2000;1016-1018.
49. Nyberg S., Farde L., Halldin C. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology. 16:1997;1-7.
50. Pletscher A. Platelets as models: use and limitations. Experientia. 44:1988;152-155.
51. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol. Rep. 10:1962;799-812.
52. Rappaport M., Hopkins H.K., Hall K., Belleza T., Hall R.A. Schizophrenia and evoked potentials: maximum amplitude, frequency of peaks, variability and phenothiazine effects. Psychophysiology. 12:1975;196-207.
53. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J. Clin. Psychiatry. 60(Suppl. 10):1999;5-14.
54. Scherg M., Picton T.W. Separation and identification of event-related potential components by brain electric source analysis. Brunia C.H.M., Mulder G., Verbaten M.N. Event-Related Brain Research (EEG Suppl. 42). 1991;24-37 Elsevier, Amsterdam.
55. Scherg M., von Cramon D. Two bilateral sources of the late AEP as identified by a spatio-temporal dipole model. Electroencephalogr. Clin. Neurophysiol. 62:1985;32-44.
56. Scherg M., von Cramon D. Dipole source potentials of the auditory cortex in normal subjects and in patients with temporal lobe lesions. Grandori F., Hoke M., Romani G.L. Auditory Evoked Magnetic Fields and Electric Potentials (Adv. Audiol.). vol. 6:1990;165-193 Karger, Basel.
57. Schooler C., Buchsbaum M.S., Carpenter W.T. Evoked response and kinesthetic measures of augmenting/reducing in schizophrenics: replications and extensions. J. Nerv. Ment. Dis. 163:1976;221-232.
58. Siever L.J., Kahn R.S., Lawlor B.A., Trestman R.L., Lawrence T.L., Coccaro E.F. Critical issues in defining the role of serotonin in psychiatric disorders. Pharmacol. Rev. 43:1991;509-525.
59. Spoont M.R. Modulatory role of serotonin in neural information processing: Implications for human psychopathology. Psychol. Bull. 112:1992;330-350.
60. Tuchtenhagen F., Daumann J., Norra C., Gobbele R., Becker S., Pelz S., Saß H., Buchner H., Gouzoulis-Mayfrank E. High intensity dependence of auditory evoked dipole source activity indicates decreased serotonergic activity in abstinent ecstasy (MDMA) users. Neuropsychopharmacology. 22:2000;608-617.
61. Van Praag H.M., Lemus C., Kahn R. Hormonal probes of central serotonergic activity: do they really exist? Biol. Psychiatry. 22:1987;86-98.
62. Van Tol H.H., Bunzow J.H., Guan H.C., Sunahara R.K., Seeman P., Niznik H.B., Civelli O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature. 350:1991;610-614.
63. VanVeelen N.M.J., Kahn R.S. Dopamine, serotonin and schizophrenia. Adv. Neurol. 80:1999;425-429.
64. Widerlöv E. A critical appraisal of CSF monoamine metabolite studies in schizophrenia. Ann. N.Y. Acad. Sci. 537:1988;309-323.
65. Yatham L.N., Steiner M. Neuroendocrine probes of serotonergic function: a critical review. Life Sci. 53:1993;447-463.